Therapeutic potential of pregnenolone and pregnenolone methyl ether on depressive and CDKL5 deficiency disorders: Focus on microtubule targeting
Open Access
- 19 August 2021
- journal article
- review article
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 34 (2) , e13033
Abstract
Pregnenolone methyl‐ether (PME) is a synthetic derivative of the endogenous neuroactive steroid pregnenolone (PREG), which is an important modulator of several brain functions. In addition to being the precursor of steroids, PREG acts directly on various targets including microtubules (MTs), the functioning of which is fundamental for the development and homeostasis of nervous system. The coordination of MT dynamics is supported by a plethora of MT‐associated proteins (MAPs) and by a specific MT code that is defined by the post‐translational modifications of tubulin. Defects associated with MAPs or tubulin post‐translational modifications are linked to different neurological pathologies including mood and neurodevelopmental disorders. In this review, we describe the beneficial effect of PME in major depressive disorders (MDDs) and in CDKL5 deficiency disorder (CDD), two pathologies that are joint by defective MT dynamics. Growing evidence indeed suggests that PME, as well as PREG, is able to positively affect the MT‐binding of MAP2 and the plus‐end tracking protein CLIP170 that are both found to be deregulated in the above mentioned pathologies. Furthermore, PME influences the state of MT acetylation, the deregulation of which is often associated with neurological abnormalities including MDDs. By contrast to PREG, PME is not metabolised into other downstream molecules with specific biological properties, an aspect that makes this compound more suitable for therapeutic strategies. Thus, through the analysis of MDDs and CDD, this work focuses attention on the possible use of PME for neuronal pathologies associated with MT defects.Keywords
Funding Information
- Institute on Aging, University of Pennsylvania (CDKL5 ‐ 17 ‐ 104 ‐ 01.)
This publication has 94 references indexed in Scilit:
- Pregnenolone Sulfate: From Steroid Metabolite to TRP Channel LigandMolecules, 2013
- Altered expression of synapse and glutamate related genes in post-mortem hippocampus of depressed subjectsInternational Journal of Neuropsychopharmacology, 2013
- Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in miceProceedings of the National Academy of Sciences, 2012
- 3β-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disordersProceedings of the National Academy of Sciences, 2012
- What We Know and Would Like to Know about CDKL5 and Its Involvement in Epileptic EncephalopathyNeural Plasticity, 2012
- CDKL5, a Protein Associated with Rett Syndrome, Regulates Neuronal Morphogenesis via Rac1 SignalingThe Journal of Neuroscience, 2010
- Phosphorylation Controls Autoinhibition of Cytoplasmic Linker Protein-170Molecular Biology of the Cell, 2010
- Association of Anxiety and Depression With Microtubule-Associated Protein 2– and Synaptopodin-Immunolabeled Dendrite and Spine Densities in Hippocampal CA3 of Older HumansArchives of General Psychiatry, 2010
- CDKL5 Expression Is Modulated during Neuronal Development and Its Subcellular Distribution Is Tightly Regulated by the C-terminal TailJournal of Biological Chemistry, 2008
- Suppression of MAP2 in cultured cerebeller macroneurons inhibits minor neurite formationNeuron, 1992